(Q42213760)

18 October 2017

title

The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance (English)

1 reference

18 October 2017

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

author name string

Huihui Chong

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Xue Yao

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Zonglin Qiu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jianping Sun

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Yuanyuan Qiao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Meng Zhang

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Meitian Wang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Yuxian He

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

language of work or name

English

0 references

publication date

7 June 2014

1 reference

Journal of Antimicrobial Chemotherapy

18 October 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

2759-2769

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24908047%20AND%20SRC:MED&resulttype=core&format=json

HIV drug development: the next 25 years

7 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

The structural biology of HIV-1: mechanistic and therapeutic insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

21 January 2018

HIV entry inhibitors.

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

HIV-1 Entry, Inhibitors, and Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Maraviroc for previously treated patients with R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Resistance to enfuvirtide, the first HIV fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Is there a future for antiviral fusion inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Peptides in the treatment of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Inhibition of HIV-1 by fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Core structure of gp41 from the HIV envelope glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Atomic structure of a thermostable subdomain of HIV-1 gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Atomic structure of the ectodomain from HIV-1 gp41

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Broad Antiviral Activity and Crystal Structure of HIV-1 Fusion Inhibitor Sifuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Discovery of Critical Residues for Viral Entry and Inhibition through Structural Insight of HIV-1 Fusion Inhibitor CP621-652

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

The M-T Hook Structure Is Critical for Design of HIV-1 Fusion Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Short-peptide fusion inhibitors with high potency against wild-type and enfuvirtide-resistant HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Molecular strategies to design an escape-proof antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Selection of T1249-resistant human immunodeficiency virus type 1 variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183

Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKU183